Chu Hsien Lim

Chu Hsien Lim


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2020 in eLife
Verified
Journal Article
Open access
CLChu Hsien Lim
Chu Hsien Lim
PKPrameet Kaur
Prameet Kaur
ETEmelyne Teo
Emelyne Teo
VLVanessa Yuk Man Lam
Vanessa Yuk Man Lam
FZFangchen Zhu
Fangchen Zhu
NTNicholas Tolwinski
Nicholas Tolwinski
The brains of Alzheimer’s disease patients show a decrease in brain mass and a preponderance of extracellular Amyloid-β plaques. These plaques are formed by aggregation of polypeptides that are derived from the Amyloid Precursor Protein (APP). Amyloid-β plaques are thought to play either a direct or an indirect role in disease progression, however the exact role of aggregation and plaque formation in the aetiology of Alzheimer’s disease (AD) is subject to debate as the biological effects of soluble and aggregated Amyloid-β peptides are difficult to separate in vivo. To investigate the consequences of formation of Amyloid-β oligomers in living tissues, we developed a fluorescently tagged, optogenetic Amyloid-β peptide that oligomerizes rapidly in the presence of blue light. We applied this system to the crucial question of how intracellular Amyloid-β oligomers underlie the pathologies of A. We use Drosophila, C. elegans and D. rerio to show that, although both expression and induced oligomerization of Amyloid-β were detrimental to lifespan and healthspan, we were able to separate the metabolic and physical damage caused by light-induced Amyloid-β oligomerization from Amyloid-β expression alone. The physical damage caused by Amyloid-β oligomers also recapitulated the catastrophic tissue loss that is a hallmark of late AD. We show that the lifespan deficit induced by Amyloid-β oligomers was reduced with Li+ treatment. Our results present the first model to separate different aspects of disease progression.

22 December 2017 in Journal of Developmental Biology
Verified
Journal Article
Open access
PDF file
CLChu Hsien Lim
Chu Hsien Lim
Ajay S. MathuruAjay S. Mathuru
Ajay S. Mathuru
Modeling human disease in animals is an important strategy to discover potential methods of intervention. We suggest that there is much to be gained by employing a multi-model approach that takes advantage of different animal systems used in the laboratory simultaneously. We use the example of modeling Alzheimer’s disease in Drosophila melanogaster, Caenorhabditis elegans, and Danio rerio to illustrate how such an approach can be employed to investigate the pathophysiology of the disease.

1 August 2018
Verified
Report
Closed access
CLChu Hsien Lim
Chu Hsien Lim
BKBrian Kangas
Brian Kangas
JBJack Bergman
Jack Bergman
Cancer patients experience a higher rate of depression and anxiety which can result in negative healthcare outcomes. With the limited treatment options available, there has been an interest in using psychedelics such as psilocybin to manage such complications. Recently, two studies demonstrated the potential of psilocybin in not only reducing distress, but also increasing positive emotions in cancer patients. It is thus interesting to further examine this issue. This review paper will first provide a brief introduction to psilocybin and proceed to summarize key findings from these two studies.